1. Home
  2. HEI vs ARGX Comparison

HEI vs ARGX Comparison

Compare HEI & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heico Corporation

HEI

Heico Corporation

HOLD

Current Price

$337.92

Market Cap

44.2B

Sector

Industrials

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$848.14

Market Cap

52.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HEI
ARGX
Founded
1957
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.2B
52.6B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
HEI
ARGX
Price
$337.92
$848.14
Analyst Decision
Buy
Strong Buy
Analyst Count
13
19
Target Price
$361.58
$971.89
AVG Volume (30 Days)
464.6K
322.5K
Earning Date
12-18-2025
10-30-2025
Dividend Yield
0.07%
N/A
EPS Growth
33.52
N/A
EPS
4.90
23.27
Revenue
$4,485,044,000.00
$3,683,281,000.00
Revenue This Year
$10.37
$91.22
Revenue Next Year
$7.74
$36.36
P/E Ratio
$68.96
$33.87
Revenue Growth
16.26
92.98
52 Week Low
$216.68
$510.06
52 Week High
$339.81
$934.62

Technical Indicators

Market Signals
Indicator
HEI
ARGX
Relative Strength Index (RSI) 67.64 40.10
Support Level $306.08 $843.03
Resistance Level $318.55 $863.11
Average True Range (ATR) 7.75 16.75
MACD 3.39 -6.68
Stochastic Oscillator 93.87 24.19

Price Performance

Historical Comparison
HEI
ARGX

About HEI Heico Corporation

Heico is an aerospace and defense supplier that focuses on creating replacement parts for commercial aircraft and components for defense products. In commercial aerospace, Heico is the largest independent producer of replacement aircraft parts. In the defense market, the company produces niche subcomponents used in targeting technology as well as simulation equipment, among other categories. It operates as two segments: the flight support group,or FSG, and the electronic technologies group, or ETG, both of which supply the aerospace and defense sectors to different degrees. The company is persistently acquisitive, focusing on companies in similar or adjacent markets that offer strong cash flow and profitable growth potential.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: